{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-24-110552","form_type":"8-K","ticker":"TELA","cik":"0001561921","company_name":"TELA Bio, Inc.","filed_at":"2024-10-22T23:59:59+00:00","discovered_at":"2026-05-14T18:03:08.791384+00:00","generated_at":"2026-05-30T11:38:28.801328+00:00","sec_items":["2.02","7.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"TELA Bio reports preliminary Q3 revenue of $19M (+26% YoY); implements cost cuts","bullets":["Revenue $19.0M for Q3 2024 vs $15.1M in Q3 2023, a 26% increase.","Gross margin ~68% vs 69% in prior-year quarter.","Cash and equivalents $17.3M at Sept 30, 2024, down from $46.7M at Dec 31, 2023.","Cost-cutting measures expected to reduce FY2025 operating expenses by $5M-$10M annualized."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-24-110552","json":"https://secwatch.observer/filing/0001104659-24-110552.json","markdown":"https://secwatch.observer/filing/0001104659-24-110552.md","text":"https://secwatch.observer/filing/0001104659-24-110552.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1561921/000110465924110552/0001104659-24-110552-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1561921/000110465924110552/tm2426600d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-30T11:38:28.801328+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}